Guselkumab Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the QUASAR Phase 3 Induction Study

被引：0

作者：

Bressler, Brian ^{[1
]}

Feagan, Brian G. ^{[2
]}

Panes, Julian ^{[3
]}

Lichtenstein, Gary R. ^{[4
]}

Huang, Kuan-Hsiang G. ^{[5
]}

Germinaro, Matthew ^{[5
]}

Pandya, Dwiti ^{[5
]}

Han, Chenglong ^{[6
]}

Miao, Ye ^{[5
]}

Zhang, Hongyan ^{[5
]}

Lateef, Syed ^{[7
]}

Petroniene, Rima ^{[8
]}

Rayyan, Yaser ^{[9
]}

Peyrin-Biroulet, Laurent ^{[10
,11
]}

Rubin, David T. ^{[12
]}

Hisamatsu, Tadakazu ^{[13
]}

机构：

[1] St Pauls Hosp, Vancouver, BC, Canada

[2] Western Univ, London, ON, Canada

[3] Hosp Clin Barcelona, Inst Invest Biomed August Pi I Sunyer, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Catalonia, Spain

[4] Univ Penn, Philadelphia, PA USA

[5] Janssen Res & Dev LLC, Spring House, PA USA

[6] Janssen Global Serv LLC, Malvern, PA USA

[7] Gastro Hlth, Kissimmee, FL USA

[8] Barrie GI Associates, Barrie, ON, Canada

[9] Univ Jordan, Amman, Jordan

[10] Lorraine Univ, CHU Nancy, Vandoeuvre Les Nancy, Lorraine, France

[11] Lorraine Univ, Last Inserm U954, Vandoeuvre Les Nancy, Lorraine, France

[12] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA

[13] Kyorin Univ, Sch Med, Tokyo, Tokyo, Japan

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S1060

引用

页码：S807 / S808

页数：2

共 50 条

[41] Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
Sandborn, W. J.
Ferrante, M.
Bhandari, B. R.
Berliba, E.
Hibi, T.
D'Haens, G. Geert R.
Tuttle, J.
Krueger, K.
Friedrich, S.
Durante, M.
Arora, V.
Feagan, B.
JOURNAL OF CROHNS & COLITIS, 2019, 13 : S54 - S54
[42] Corticosteroid Sparing Effects of Treatment With Guselkumab in Patients With Moderate to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results Through Week 44
Bressler, Brian
Allegretti, Jessica R.
Rubin, David T.
Shipitofsky, Nicole
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Wilson, Rebbecca
Zhang, Hongyan
Armuzzi, Alessandro
Fishman, Sigal
Wang, Yufang
Panes, Julian
Lichtenstein, Gary R.
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1002 - S1002
[43] Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study
Danese, S.
Vermeire, S.
Zhou, W.
Pangan, A.
Siffledeen, J.
Hebuterne, X.
Nakase, H.
Higgins, P.
Chen, M. H.
Sanchez-Gonzalez, Y.
Huang, B.
Xie, W.
Liu, J.
Weinreich, M.
Pannaccione, R.
JOURNAL OF CROHNS & COLITIS, 2021, 15 : S022 - S024
[44] Predictors of health-related quality of life in patients with moderate to severely active ulcerative colitis receiving biological therapy
Rasmussen, Bjorn
Haastrup, Peter
Wehberg, Sonja
Kjeldsen, Jens
Waldorff, Frans Boch
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2020, 55 (06) : 656 - 663
[45] Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 U-ACHIEVE Study
Danese, Silvio
Vermeire, Severine
Zhou, Wen
Pangan, Aileen
Siffledeen, Jesse
Hebuterne, Xavier
Nakase, Hiroshi
Chen, Minhu
Higgins, Peter
Sanchez-Gonzalez, Yuri
Huang, Bidan
Xian, Wangang
Liu, Jianzhong
Weinreich, Michael
Panaccione, Remo
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S312 - S313
[46] PRA023 Improved Health-Related Quality of Life as Measured by IBDQ-32 in a Phase 2 Trial in Patients with Moderately to Severely Active Ulcerative Colitis
Rubin, David T.
Sands, Bruce E.
Peyrin-Biroulet, Laurent
Danese, Silvio
Nguyen, Deanna D.
Dinh, Quinn
Dong, Bin
Ma, Christopher
Ritter, Timothy E.
Panaccione, Remo
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S678 - S678
[47] Predictors of health-related quality of life in patients with moderate to severely active ulcerative colitis receiving biological therapy
Rasmussen, B.
Haastrup, P.
Wehberg, S.
Kjeldsen, J.
Waldorff, F. Boch
JOURNAL OF CROHNS & COLITIS, 2019, 13 : S506 - S507
[48] Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study
Vermeire, S.
Danese, S.
Zhou, W.
Pangan, A.
Greenbloom, S.
D'Haens, G.
Panes, J.
Juillerat, P.
Lindsay, J. O.
Loftus, E. V., Jr.
Sandborn, W. J.
Reinisch, W.
Gonzalez, Y. Sanchez
Huang, B.
Xie, W.
Liu, J.
Weinreich, M. A.
Panaccione, R.
JOURNAL OF CROHNS & COLITIS, 2021, 15 : S021 - S022
[49] Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study
Vermeire, Severine
Danese, Silvio
Zhou, Wen
Pangan, Aileen
Greenbloom, Susan
D'Haens, Geert
Panes, Julian
Juillerat, Pascal
Lindsay, James
Loftus, Edward V.
Sandborn, William
Reinisch, Walter
Sanchez-Gonzalez, Yuri
Huang, Bidan
Xian, Wangang
Liu, Jianzhong
Weinreich, Michael
Panaccione, Remo
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S357 - S357
[50] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-1 study
Andrews, J. M.
D'Haens, G.
Kobayashi, T.
Morris, N.
Lissoos, T.
Hoover, A.
Li, X.
Arora, V.
Milch, C.
Sandborn, W. J.
Sands, B. E.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 132 - 133

← 1 2 3 4 5 →